Results 51 to 60 of about 793,626 (282)

Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants.

, 2009
Intermittent preventive treatment in infants (IPTi) is an effective and safe malaria control strategy. However, it remains unclear what antimalarials should be used to replace sulfadoxine-pyrimethamine (SP) when and where SP is no longer an effective ...
Cairns, Matthew, Gosling, Roly, Gesase, Samwel, Mosha, Jacklin, Greenwood, Brian, Chandramohan, Daniel   +5 more
core   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

Network-based prediction of anti-cancer drug combinations

Frontiers in Pharmacology
Drug combinations have emerged as a promising therapeutic approach in cancer treatment, aimed at overcoming drug resistance and improving the efficacy of monotherapy regimens.
Jue Jiang, Xuxu Wei, YuKang Lu, Simin Li, Xue Xu   +4 more
doaj   +1 more source

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland—Does Variation Matter?

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.
Suzanne Tugnait, R. Al‐Saadi, A. Lopez‐Cortes, K. Dzhuma, M. Oostveen, J. Brok, S. Irtan, M. Weeks, J. Bate, S. Baker, R. Williams, M. Powis, D. Saunders, O. Olsen, T. Watson, S. Shelmerdine, S. Vaidya, L. Howell, C. Duncan, G. M. Vujanic, C. Stiller, G. P. Balchin, T. Chowdhury, K. Pritchard‐Jones   +23 more
wiley   +1 more source

Changes in kidney function in a population with essential hypertension in real life settings [PDF]

, 2017
Introduction. Hypertension has been identified as one of the commonest modifiable determinants for chronic kidney disease progression. A variety of antihypertensive drugs are available and their effect on kidney function has been investigated by a ...
Haidich, Anna-Bettina, Lasaridis, Anastasios N., Mark, Patrick B., Pikilidou, Maria I., Ptinopoulou, Anastasia G., Tziolas, Ioannis M., Zebekakis, Pantelis E.   +6 more
core  

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. [PDF]

, 2018
Dysregulation of the PI3K-AKT-mTOR signaling network is a prominent feature of breast cancers. However, clinical responses to drugs targeting this pathway have been modest, possibly because of dynamic changes in cellular signaling that drive resistance ...
A Bosch, A Katsha, A Subramanian, AA Dar, Andrei Goga, AS Nikonova, AV Statsuk, AY Choo, B MacLean, C Leroy, Cancer Genome Atlas Network., D Bankston, DA Fruman, F Janku, F Zheng, GR Anderson, H Daub, H Yang, Hayley J. Donnella, J Baselga, J Foucquier, J Hollander den, J Lehár, JA Diehl, James E. Korkola, James T. Webber, JE Ferrell Jr., JF Blake, John D. Gordan, JS Duncan, KE O’Reilly, Kevan M. Shokat, Khyati N. Shah, KJ Brewer Savannah, L Boussemart, L Lu, L Vadlakonda, LL Liu, M Bantscheff, M Barvian, M Choi, M Elkabets, M Laplante, M Piccart, M Tanaka, MJ West, MK Muellner, ML Sos, MM Martins, N Dey, N Ilic, N Volkmann, Nora Bayani, Olga Momcilovic, P Liu, PM Barr, PP Roux, QB She, R Sears, RB Corcoran, Rebecca S. Levin, RM Neve, Roman Camarda, SJ Klempner, SMA Lens, Sourav Bandyopadhyay, SR Vora, TJ Stuhlmiller, TK Nomanbhoy, Y Zwang   +69 more
core   +1 more source

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson, Ingrid Winship, Gary Hammerschlag, Laura Scardamaglia   +3 more
wiley   +1 more source

One-Step Generation of a Drug-Releasing Hydrogel Microarray-On-A-Chip for Large-Scale Sequential Drug Combination Screening [PDF]

, 2019
Large-scale screening of sequential drug combinations, wherein the dynamic rewiring of intracellular pathways leads to promising therapeutic effects and improvements in quality of life, is essential for personalized medicine to ensure realistic cost and ...
Bae, Hyung Jong, Jeong, Yunjin, Kim, Jiyun, Kim, Su Deok, Kwon, Sunghoon, Lee, Amos Chungwon, Lee, Daewon, Lee, Sumin, Lee, Yongju, Oh, Dong Yoon, Song, Seo Woo   +10 more
core   +1 more source

Preferences of Pediatric Patients and Their Caregivers for Chemotherapy‐Induced Nausea and Vomiting Control Endpoints: A Mixed Methods Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Although not always achieved, complete chemotherapy‐induced nausea and vomiting (CINV) control is the conventional goal of CINV prophylaxis. In this two‐center, mixed‐methods study, we sought to understand the preferences of adolescent patients and family caregivers for CINV control endpoints.
Haley Newman, Tadi Hondonga, Alison Berry, Caitlin Elgarten, Jason Freedman, Katelyn Oranges, Sara McDonough, Caroline Diorio, L. Lee Dupuis   +8 more
wiley   +1 more source

A comprehensive review of cluster methods for drug–drug interaction network

Quantitative Biology
The detection of drug–drug interaction (DDI) is crucial to the rational use of drug combinations. Experimentally, DDI detection is time‐consuming and laborious.
Shuyuan Cao, Guixia Liu, Xiangrun Zhou, Ji Lv   +3 more
doaj   +1 more source